Sense Biodetection Limited, a Cambridge, UK-based molecular diagnostics company, raised £12.3m in funding.
The round included:
– £10.5m Series A investment co-led by Cambridge Innovation Capital (CIC) and Earlybird, with participation from Jonathan Milner and seed round investor Mercia Asset Management, and
– a grant of £1.8m from Innovate UK.
The company plans to invest the new funds in the development and manufacture of a range of tests utilising its novel and proprietary rapid molecular amplification technology, targeting in the first instance infectious disease applications such as influenza (flu).
Founded in 2014 by Harry Lamble and Ralph Lamble, Sense Biodetection is a molecular diagnostics company that develops instrument-free, point-of-care molecular diagnostic tests.
The company’s handheld tests remove the need for advanced hardware to determine a result. Sense operates from bespoke laboratory, development and manufacturing facilities in Cambridge and Oxford, UK.